SCHEMBL8336407

SCHEMBL8336407

N[C@H]1CCN(O)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL253915 1.00
SCHEMBL1897868 1.00
SCHEMBL7955778 0.86
SCHEMBL2399791 0.72
SCHEMBL7418051 0.72
SCHEMBL75546 0.70
SCHEMBL3183061 0.70
SCHEMBL75545 0.70
SCHEMBL22567117 0.70
SCHEMBL8565574 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150119327-A1 DRUG SCREENING PLATFORM FOR RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-04-30 US claimed
EP-2841067-A2 A DRUG SCREENING PLATFORM FOR RETT SYNDROME The Regents of The University of California (US) 2015-03-04 EP claimed
WO-2013163455-A2 A DRUG SCREENING PLATFORM FOR RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-10-31 WO claimed
US-12121526-B2 Targeting NCCA-ATP channel for organ protection following ischemic episode THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2024-10-22 US disclosed
US-20230142111-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-11 US disclosed
US-20220193096-A1 INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-06-23 US disclosed
US-9034798-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2015-05-19 US disclosed
US-20150119327-A1 DRUG SCREENING PLATFORM FOR RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-04-30 US disclosed
EP-2259068-B1 Capture compounds and methods for analyzing the proteome CAPROTEC BIOANALYTICS GMBH (DE) 2013-08-14 EP disclosed
US-7858560-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2010-12-28 US disclosed
EP-2259068-A2 Capture compounds and methods for analyzing the proteome caprotec bioanalytics GmbH (DE) 2010-12-08 EP disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
EP-1485707-B1 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS CAPROTEC BIOANALYTICS GMBH (DE) 2009-01-14 EP disclosed
WO-2004041776-A2 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-21 WO disclosed
EP-0318091-B1 RESOLVED AMINO PYRROLIDINE NEUROPROTECTIVE AGENTS MERCK SHARP & DOHME LTD. (GB) 1992-12-09 EP disclosed
US-4863953-A [3R]-3-amino-1-hydroxy pyrrolidin-2-one and its use as a neuroprotective agent MERCK & CO., INC. (US) 1989-09-05 US disclosed
EP-0318091-A2 Resolved amino pyrrolidine neuroprotective agents MERCK SHARP & DOHME LTD. (GB) 1989-05-31 EP disclosed